Reevo S.P.A. (REEVO.MI)

Milan - Milan Prezzo differito. Valuta in EUR.

Aggiungi a watchlist

13,55

-0,10

(-0,73%)

Alla chiusura: 05:00PM CET

Capitalizzazione	67,706M
Beta (5 anni mensile)	N/D
Rapporto PE (ttm)	39,85
EPS (ttm)	0,34
Prossima data utili	N/D
Rendimento e dividendo (forward)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	19,50

Tutte

GlobeNewswire
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
– FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa –– PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations is open for enrollment – LOS ANGELES, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the launch and commercial availability of its first proprietary produ